Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen for diabetic foot ulcers
NCT02538705Phase 2Completed
- Sponsor
- Artgen Biotech
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neovasculgen in diabetic foot ulcer (DFU), sponsored by Artgen Biotech. Primary endpoint: Area of diabetic foot ulcers at 180 days. Started Aug 2015; status: completed.
02
Drugs
neovasculgen
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02538705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538705.